How have diagnostic tools and therapies, such as PSMA, MRI, fusion biopsies, genomic classifiers, and second gen anti-androgens, changed those outcome...
New comment by Radiation Oncologist at National Institutes of Health Clinical Center ( December 15, 2024)
Hi Dr. @Poole,
For patients with newly diagnosed, M1a/low-volume M1b disease by conventional imaging, the 5-yr OS was 65% (median survival ≈ 7 yrs) in STAMPEDE fo...